University of Minnesota
https://twin-cities.umn.edu/
612-625-5000
Milestone
3.3.b

Immune response in the very young

In progress
High priority

Determine, through clinical studies, if adjuvants substantially improve vaccine efficacy in the very young, and assess their safety profiles.

Progress Highlights

Clemens 2022 found that inclusion of TLR7/8 adjuvant R848 in an inactivated IAV vaccine can promote a lasting IgG response to the HA stem.

See research


US CDC is conducting studies in Peru to assess if enhanced vaccines can overcome low antibody responses, randomizing adjuvanted vs standard egg-based influenza vaccine. 


Seqirus is sponsoring a Phase 2 trial to evaluate responses to vaccination with different MF59 adjuvanted pandemic influenza vaccine formulations of an H5N1 vaccine in pediatric subjects (NCT04669691).

See clinical trial

Barman 2022 found that individually encapsulated and admixed cGAMP-PS and CL075-PS shape the quantity and quality of neonatal immune responses and Th1 polarized neonatal rHA-specific humoral and cell-mediated immune responses [preclinical study in mice]

See research